Last reviewed · How we verify
FLU-Q-PAN H7N9 Formulation 2
FLU-Q-PAN H7N9 Formulation 2 is a vaccine designed to protect against H7N9 influenza.
FLU-Q-PAN H7N9 Formulation 2 is a vaccine designed to protect against H7N9 influenza. Used for Protection against H7N9 influenza.
At a glance
| Generic name | FLU-Q-PAN H7N9 Formulation 2 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious disease |
| Phase | Phase 2 |
Mechanism of action
It works by stimulating the body's immune system to produce antibodies against the H7N9 virus, providing immunity against future infections.
Approved indications
- Protection against H7N9 influenza
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older (PHASE2)
- Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLU-Q-PAN H7N9 Formulation 2 CI brief — competitive landscape report
- FLU-Q-PAN H7N9 Formulation 2 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI